Digital ulcers (DUs) are a common visible manifestation of the progressive vascular disease that characterizes the SSc disease process. DUs not only impact significantly on patients' quality of life and hand function, but are also a biomarker of internal organ involvement and of disease severity. The aetiology of (digital) vascular disease in SSc is multifactorial, and many of these factors are potentially amenable to therapeutic intervention. The management of DU disease in SSc is multifaceted. Patient education and non-pharmacological interventions (e.g. smoking cessation) should not be neglected. There are a number of drug therapies available to prevent (e.g. phosphodiesterase type-5 inhibitors and ET receptor-1 antagonists) and treat (e.g. i.v. iloprost) DUs. DUs are also important for two other reasons: firstly, as a primary end point in SSc-related clinical trials; and secondly, DUs are included in the ACR/EULAR SSc classification criteria. However, the reliability of rheumatologists to grade DUs is poor to moderate at best, and this poses challenges in both clinical practice and research. The purpose of this review is to provide the reader with a description of the spectrum of DU disease in SSc including pathophysiology, epidemiology and clinical burden, all of which inform the multifaceted approach to management.
Introduction
Digital ulcers (DUs) are common in patients with SSc and responsible for much of the pain and morbidity associated with the disease. DUs are also a biomarker of internal organ involvement and mortality, even in early disease. There are now a number of effective drug therapies available both to prevent and to treat DUs. The purpose of this review is to describe the spectrum of DU disease in patients with SSc and the multifaceted approach to management, including drug therapies.
DUs in SSc
Pathophysiology Vascular disease plays a central role in the pathogenesis of SSc, including DUs and many of the organ-based complications [1, 2] , and in the digits involves both microvessels and digital arteries [3] . The key pathophysiological factors driving vascular disease in SSc are depicted in Fig. 1 . Fingertip DUs are believed to be ischaemic, whereas those over the extensor aspect of the hands (in particular, over the small joints) are commonly believed to be mechanical, as a result of recurrent microtrauma and increased skin tension (Fig. 2) [4]. Dysfunctional arteriovenous anastomoses may be implicated in the pathogenesis of DUs [5] . An increased prevalence of macrovascular disease proximal to the digital artery has been reported in SSc [6] , in particular affecting the ulnar artery and associated with an increased risk of DUs [7, 8] . Kato et al. [9] reported in a small study of 10 patients that a reduced ankle brachial index (reflecting macrovascular disease) is associated with DUs of the feet and with (lower) skin perfusion pressure. DUs may also develop in relation to s.c. calcinosis, not uncommonly associated with a local inflammatory response and the discharge of calcinotic material (Fig. 2) .
Epidemiology
DUs are common in SSc, with around half of patients reporting a history of DUs [4, 1012] and $10% having a current DU [12, 13] . DUs may often occur early in the course of the disease, within the first year from the first non-RP symptoms [4] . Patients with a shorter duration between their first and second DUs (in particular if the second is within 2 years) have a higher (yearly) DU burden [4] . In a single-centre longitudinal retrospective study including 103 patients with SSc, 43 and 73% of patients developed their first DU within 1 and 5 years, respectively, of the first non-RP symptoms [4] . In a prospective longitudinal analysis including 695 patients from the EUSTAR (EULAR Scleroderma Trials and Research) database, 70% of patients reported a history of DU after 10 years of follow-up [14] . Data from the DU outcomes (DUO) register (a European, prospective, multicentre, observational registry of SSc patients with DU disease, irrespective of treatment) demonstrated that patients with anti-Scl-70 antibody developed DUs $5 years earlier than those who were anticentromere positive [15] .
Clinical burden
Between one-and two-thirds of patients with SSc develop recurrent DUs [4, 10, 16] . Patients often develop multiple DUs per episode [4, 16] , with involvement of both hands and multiple fingers [4, 17] . DUs are often slow to heal, especially if there is underlying calcinosis, and can be associated with underlying bone infection (which may be detected early by MRI) [18] . In a prospective study including 100 patients with SSc and 1614 digital lesions, the average time to DU healing was 76.2 days, whereas in calcinosis-related DUs this was 93.6 days [19] . Other factors reported to delay DU healing include infection, the presence of perilesional oedema, wet or dry necrosis, eschar, bone and tendon exposure and gangrene [19] .
DUs often occur on the thumb, index and middle fingers, although any finger can be involved [4, 17] . Amanzi et al. reported that fingertip DUs were more common than extensor DUs (52.5 vs 30%) [19] ; whereas, in a prospective study over 12 months, both types had an equal prevalence of 6% (and were equally disabling) [13] . DUs occur
FIG. 2 Digital ulcers in SSc
The spectrum of digital ulcer disease in patients with SSc: fingertip (A), extensor (B), overlying s.c. calcinosis as seen on a plain radiograph (C and D, respectively), and on the lateral aspect (E) and the nailbed of the fingers (F).
FIG. 1 The pathophysiology of vascular disease in SSc
The major contributory factors implicated in the vascular disease in SSc, many of which are amenable to therapeutic intervention. Reproduced (with modification) courtesy of Professor Fredrick Wigley, Johns Hopkins Scleroderma Center.
www.rheumatology.oxfordjournals.org less commonly on the lateral edges, nail base and palmar aspect of the digits (Fig. 2) [19] .
DUs are often exquisitely painful [13, 17] and associated with high levels of hand and global disability [13, 20, 21] . Those patients with DUs require greater support in the activities of daily living than those without [20, 22] . In a study including 2327 patients from the DUO registry, an increasing number (0, 12 and 5 3) of DUs at enrolment was associated with greater work impairment during the preceding month (28, 42 and 48%, respectively), inability to perform activities of daily living (35, 54 and 63%, respectively) and hours of paid help (mean number of hours 17.0, 35.9 and 63.7, respectively) [22] .
DUs are often infected [15] , most commonly by Staphlococcus aureus [23] . In addition, Giuggioli et al.
[23] found that $25% of DUs were infected with intestinal organisms (in particular, Escherichia coli and Enterococcus faecalis), highlighting the need for patient education to ensure meticulous wound care. Thirty-two per cent of patients enrolled in the DUO registry reported previous antibiotic therapy for soft tissue infection complicating DUs [15] . In a retrospective study, which included 248 patients with SSc, 19 of 45 (42%) infected DUs were associated with osteomyelitis, as defined by clinical and plain radiographic features [24] .
DUs as a biomarker of disease severity
It is increasingly recognized that DUs are associated with a severe disease course (including internal organ complications), even in early disease. In a multivariate analysis of 3196 patients from the EUSTAR database, a history of DUs was predictive of death (odds ratio 1.53) [25] . DUs are often present in patients fulfilling the very early diagnosis of SSc criteria [26] and are associated with gastrointestinal (oesophageal) involvement [27] .
Clinical associates of DU
The clinical and serological/vascular associates of DU development in patients with SSc are summarized in Tables 1 and 2 . Many of these have been proposed as biomarkers of DUs and deserve future prospective studies to validate their predictive ability.
Capillaroscopy to predict risk of future DUs
Nailfold capillary abnormalities have been reported to predict future DUs [28, 5053] . The application of capillaroscopy by rheumatologists is likely to expand because of increasing interest in the technique following the inclusion of capillaroscopic abnormalities in the ACR/EULAR SSc classification criteria [57, 58] .
In a study that included 66 patients with SSc, worsening capillaroscopy pattern (as defined by Cutolo et al. [59] ) was associated with a significantly increased risk of severe peripheral vascular disease, including DUs, at 1824 months (adjusted odds ratios for severe peripheral vascular disease compared with normal capillaroscopy: early = 2.52, active = 6.37 and late = 16.07) [53] . The Capillaroscopic Skin Ulcer Risk Index (CSURI) has been proposed as a quantitative tool to predict SSc-related DUs and is calculated using the total number of capillaries in the distal row, maximal loop diameter and number of megacapillaries [50] . In a multicentre validation study, the CSURI at 3 months had a specificity of 81.4% and a sensitivity of 93.0% to predict DUs [52] . Smith et al. [51] proposed a simple system based upon the mean score of capillary loss over eight fingers, with specificity and sensitivity each around 70% of predicting present/future digital trophic lesions (including DUs). Manfredi et al. [28] proposed a predictive risk chart, including DU appearance and male gender, DU history, altered CSURI and ESR, to risk stratify DU risk. Data from the prospective CAPS study, which included 623 patients from 59 centres, confirmed that abnormal capillaroscopy and history of DU of were predictive of future DUs [60] .
The definition and measurement of DUs
The reliability of grading of DUs by rheumatologists is poor to moderate at best [61, 62] , which is of concern given that DUs are often a primary end point in SSc-related clinical trials and are now included in the ACR/EULAR classification criteria for SSc [57, 58] . In a Web-based study, in which rheumatologists with an interest in SSc graded images of SSc digital lesions, intra-rater reliability was high (mean weighted k value of 0.81), whereas interrater reliability was much poorer (0.46) [61] . Several recent multicentre, placebo-controlled trials have used varying definitions of SSc-related DUs, often related to a loss of epithelium and with a discernable depth [6366] . Trials may only include DUs considered ischaemic (distal to the PIP joint and on the volar aspect of the fingers) [63, 65, 66] . DU surface measurements have been assessed as an outcome measure [63] , and assessment of hand function is an indirect measure of DU status [67] . A North American working group reported moderate reliability of DU surface area measurement using digital callipers (intra-and inter-rater intra-class correlation coefficient of 0.57 and 0.48, respectively) [62] . Laser speckle contrast analysis has been reported to enable monitoring of DU status in patients with SSc by measurement of lesion size and perfusion [68] . Ulcer definition and measurement therefore deserve further research with a view to development of guidelines and/or recommendations.
Management of DUs

General approach
Patients with SSc and DU disease should be managed by a dedicated multidisciplinary team. Patient education is crucial, and patients developing DUs should be encouraged to seek medical advice early. DUs are often infected, and there should be a low threshold to prescribe appropriate antibiotic therapy. DUs can be exceptionally painful, and patients should be prescribed sufficient (often opioidbased) analgesia. The United Kingdom Scleroderma Study Group best practice recommendations on the management of digital vasculopathy is a useful reference tool for clinicians (Fig. 3) [69] .
Non-pharmacological interventions
Patients should avoid trauma to the digits (in particular to the extensor aspects in patients with flexion contractures) to prevent DUs. Patients should be counselled regarding the importance of smoking cessation. In a study including 101 patients with SSc who responded to a questionnaire, current smokers were significantly more likely than never smokers to require debridement and admission for i.v. prostanoid therapy for digital vascular disease (odds ratios 4.5 and 3.8, respectively) [70] . Any contributory cause (e.g. large vessel disease) should be treated (Fig. 3) . Meticulous attention should be directed toward wound care, including keeping the DU clean and using a suitable dressing; if the DU is dry then attempt to wet it (alginates and antimicrobials, e.g. Suprasorb and Aquacel Ag, respectively) and vice versa for wet DUs (hydrogel and hydocolloids, e.g. Intrasite gel and Duoderm, respectively) [69] . Other non-pharmacological therapies that have been reported to be associated with DU healing in patients with SSc include hyperbaric oxygen [71] , negative pressure and acoustic therapies [72, 73] , and intermittent compression [74] . The authors of a meta-analysis on nonpharmacological therapies for SSc-related DUs highlight the limited evidence base to support these interventions and the need for further high-quality research [75] .
Pharmacological interventions
The development of (digital) vascular disease in SSc is believed to be multifactorial (Fig. 1) , and many of these factors are amenable to pharmacological intervention.
Vasoactive therapies
Vasoactive therapies are central to the pharmacological treatment of DUs. Hachulla et al.
[4] reported that vasodilator therapy significantly delayed the development of DUs (hazard ratio = 0.17, 95% CI: 0.09, 0.32). In the UK, National Health Service (NHS) England has recently approved sildenafil (now off patent) for patients with refractory or severe DU disease, followed by add-on i.v. prostanoid, and then (if these are not efficacious) bosentan [76] .
Calcium channel blockers. Calcium channel blockers have been little studied in DU healing/prevention, although many clinicians prescribe calcium channel blockers in this context (often for concomitant severe RP). In a randomized, double-blind study comparing oral nifedipine (30 mg daily for 4 weeks and then 60 mg daily for 12 weeks) and i.v. iloprost for RP (both with concomitant placebo infusions or capsules, respectively), the mean number of DUs was reduced from 4.3 to 1.4 after 16 weeks of treatment with nifedipine [77] .
FIG. 3
The UK Scleroderma Study Group Best Practice Recommendations on the management of digital ulcers in patients with SSc [69] Reproduced with permission of Oxford University Press on behalf of the British Society for Rheumatology. DU: digital ulcer; ERA: endothelin-1 receptor antagonist; PDE5: phosphodiesterase type-5.
Angiotensin-converting enzyme inhibitors. Although there is a strong therapeutic rationale for the role of angiotensinconverting enzyme inhibition in DU disease (and RP), including use as vascular remodelling agents (as used in patients with ischaemic heart disease), there is no current evidence base to support this intervention. In a multicentre, double-blind, randomized clinical trial including 210 patients with lcSSc or autoimmune RP (with a specific SSc-specific autoantibody), 23 years of treatment with quinapril was not associated with a significant reduction in the number (quinapril vs placebo) of new DUs (À0.08, 95% CI: 0.23, 0.06) [64] .
Prostanoids. Prostanoids are potent vasodilators and also inhibit platelet aggregation and vascular smooth muscle cell proliferation [78, 79] . Prostanoids can be administered by various routes: oral, i.v. and s.c.; however, side effects are common to all, including systemic hypotension, dizziness, flushing, gastrointestinal disturbance, jaw pain and myalgia. Intravenous prostanoid therapy has been reported significantly to improve DU healing and reduce the number of new DUs. In two multicentre, double-blind, randomized trials, i.v. prostanoid therapy (0.52.0 ng/kg/min over 6 h, on 5 days consecutively) was associated with significantly greater DU healing than placebo [80, 81] . The second of these studies included 126 patients who completed the course of infusions; after 3 weeks of treatment, 14.6% more patients who received iloprost than placebo had 550% healed DUs [81] . Side effects were very common, with 92% of patients receiving iloprost experiencing one or more prostanoid-related side effects (although 57% of patients receiving placebo also reported side effects) [81] .
In a multicentre, double-blind, randomized trial of continuous i.v. epoprostenol for pulmonary hypertension in SSc-spectrum disorders, patients who received epoprostenol were noted to develop 50% fewer new DUs than those receiving placebo [82] .
A single-centre, open-label trial suggested that treatment with s.c. treprostinil was associated with a reduction in new DUs [83] . However, in a subsequent multicentre, double-blind, randomized trial in 148 patients, treprostinil (compared with placebo) was not associated with a significant reduction in the number of DUs (1.37 vs 1.51) at 20 weeks (although treprostinil conferred benefit in some of the secondary end points) [84] . In a meta-analysis of therapies for DU healing and prevention, oral prostanoids (iloprost, beraprost, cisaprost and treprostinil) were not associated with a reduction in new DUs compared with placebo [85] .
Endothelin receptor-1 antagonists. ET-1 is not only a potent vasoconstrictor, but also has a marked proliferative effect on smooth muscle cells and fibroblasts, acting via two receptors (ET A and ET B ) [85] . In general, ET A and ET B found on smooth muscle cells promote vasoconstriction and hyperplasia, whereas ET B which is also found on endothelial cells promotes vasodilatation [86, 87] .
Bosentan is a dual ET-1 receptor antagonist (ERA) licensed in Europe for the treatment of pulmonary arterial hypertension and the prevention of recurrent DUs. Two large multicentre, double-blind, randomized, controlled trials demonstrated that treatment with bosentan significantly reduced the number of new DUs [63, 65] . In a randomized, double-blind, placebo-controlled study with bosentan on healing and prevention of ischaemic DUs in patients with SSc, which included 188 patients with SSc (from 41 centres), 24 weeks of treatment with bosentan (62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter) was associated with a 30% reduction in the number of new DUs [65] . The treatment effect was greatest with higher DU burden at baseline, and there was no impact on the healing of existing DUs [65] . Bosentan requires regular blood monitoring (haematology and liver function tests).
Macitentan is a dual ERA licensed for the treatment of pulmonary arterial hypertension. Two multicentre, doubleblind, randomized, controlled trials (DUAL-1 and DUAL-2), so far published only in abstract form, found no reduction in the number of new DUs from treatment with macitentan [88] .
Ambrisentan (licensed for the treatment of pulmonary arterial hypertension) is a selective ET A ERA, and in two small studies has been associated with a reduction in new DUs [89, 90] . The larger was a single-centre, open-label study, in which 20 patients with SSc received ambrisentan for 24 weeks [90] . The mean number of DUs (per patient) decreased significantly (mean number at baseline 3.1 vs 1.3 at 24 weeks), and with complete healing reported of all baseline DUs observed in 14 (out of 16) patients who completed 24 weeks of treatment.
Phosphodiesterase type-5 inhibitors. Phosphodiesterase type-5 (PDE5) inhibitors inhibit the degradation (and therefore increase the bioavailability) of cyclic GMP, with subsequent vasodilatation [91] . In a meta-analysis of DU therapies that included 31 randomized controlled trials (1989 patients), PDE5 inhibitors (based upon three included RCTs with a total of 85 patients) were associated (relative risk) with DU healing (3.28) and improvement (4.29); however, the authors commented that the studies were individually underpowered to detect a significant benefit [85] . In a recent multicentre, double-blind, randomized controlled trial, which included 84 patients, treatment with sildenafil for 12 weeks was associated with a significant reduction in the number of new DUs (0.86 vs 1.51). However, the time to DU healing (the primary end point of the study) was not reduced, which the authors attribute to the high rate of DU healing in the placebo group [66] .
Combination therapy. There are no randomized controlled trials addressing vasoactive therapies in combination for DUs. Two case reports have suggested that the combination of PDE5 inhibitors and ERA therapies (either both at low dose, or initial PDE5 inhibitor with subsequent ERA) is efficacious in refractory DU disease [92, 93] .
Other drug therapies that have been explored
Statins. In a randomized trial, which included 84 patients with SSc, 4 months of treatment with atorvastatin (40 mg; www.rheumatology.oxfordjournals.org compared with placebo) was associated with a reduction in the number of new DUs (1.6 vs 2.5) during the treatment period [94] . Further research is required before statin therapy can be recommended widely.
Anticoagulant and antiplatelet agents. In a prospective parallel-group, randomized study, 24 weeks of openlabel treatment with s.c. low-molecular-weight heparin was not associated with a significant difference in new DUs [95] . Although many clinicians prescribe antiplatelet therapy for DUs (and severe RP), there is a lack of good evidence base to support this intervention. The fact that many patients with SSc have gastrointestinal involvement with a propensity to bleeding should be taken into account when assessing the risk-to-benefit ratio for any individual patient. In a randomized, double-blind, placebo-controlled study, in which patients (n = 28) received dual antiplatelet therapy (aspirin and dipyridamole), no difference in new DUs was observed over 12 years of treatment [96] . Again, further research is required to inform treatment decisions, although studies of antiplatelet agents will be difficult to mount logistically.
Antioxidants.
A reduction in the number of DUs with open-label treatment with i.v. N-acetylcysteine has been reported [97, 98] . The larger study [98] was a prospective, open-label, observational study, which included 50 patients with SSc; treatment with N-acetylcysteine (median duration of 3 years) was associated with a significant reduction in the number of DUs from 4.5 pre-treatment to 0.81 on N-acetylcysteine. Oxidant stress has been implicated in the pathogenesis of SSc, and therefore, antioxidant therapy warrants further study.
Surgical strategies
General approach
Surgical intervention is required only in a minority of patients with DU, usually in those who have failed medical management. Practice varies internationally. In a survey of 334 SScinterested rheumatologists (with 137 responders to this question), 85% of North Americans compared with 37% of Europeans reported that they never or rarely debrided DUs [62] . The main aim of debridement is to relieve pain by removing necrotic tissue and/or pus. Despite therapeutic intervention, amputation of the affected digit may be necessary [4, 15] . A significant minority of patients enrolled in the DUO register reported a history of previous debridement (9.5%) or of gangrene (22.6%) complicating DU disease [15] . Indications for surgical intervention include failure of DU healing, severe pain, osteomyelitis and underlying calcinosis. MRI is a useful tool for the early detection of osteomyelitis [18] . Perioperative pain management during debridement often requires opioid therapy [99] .
Sympathectomy and injection of botulinum toxin
There is increasing experience worldwide with these techniques for the treatment of DUs, although the evidence base in SSc-related digital vasculopathy is relatively poor (mainly retrospective case series) [100, 101] . Thoracic sympathectomy is no longer recommended for RP or DU disease (owing to the high rate of adverse effects). Peripheral (digital) sympathectomy has been reported to prevent and heal DUs in patients with SSc [102104] . In a retrospective analysis of 26 patients with DUs, improvement in pain was reported in 92.3% post-sympathectomy, with DU healing in the majority, and with only two patients later requiring surgical intervention (at 6 months and 4.5 years) [104] . Digital sympathectomy is a highly specialized procedure available only in certain centres.
Botulinum toxin has also been reported to be associated with the healing and prevention of DUs in SSc [105107] . In a prospective study of botulinum toxin, in five patients with refractory DU disease, all DUs had healed by 12 weeks (and one within 2 weeks) [105] . The results of controlled trials of botulinum toxin therapy are awaited.
Other therapies
Local therapies
There is a strong therapeutic rationale to develop locally acting therapies that are well tolerated (from lack of significant systemic vasodilatation), reducing the need for hospitalization.
In one open-label study, 27 patients were randomized to receive standard wound care with or without topical vitamin E gel. Vitamin E gel was associated with faster DU healing (13.2 weeks treated vs 20.9 weeks untreated), faster resolution of pain and fewer medications (including reduced cost of therapies) [108] . Ozgocmen et al. [109] reported that topical lidocaine was effective in controlling pain from severe DU disease in a patient with SSc (allowing the application of topical antibiotic therapy). Digital iontophoresis (using an electrical current to drive drug delivery through the skin) of treprostinil was reported to be a safe and effective method to increase skin blood flow in healthy controls and patients with SSc [110] and may in the future offer a novel approach to therapy. Waon therapy (essentially a high-temperature sauna) over 11 weeks was effective in treating a refractory toe DU [111] . Inoue et al. [112] reported the use of oral psoralen and ultraviolet A therapy in a patient with severe DU disease. Treatment three times daily for 4 weeks was well tolerated and associated with an improvement in the DU, and with loosening of collagen bundles on skin biopsy. In summary, current experience of local therapies relates mainly to anecdotal reports and small series, but the recent increasing interest in local therapies is encouraging.
Autologous fat grafting and stem cell transplant
Two small studies have reported an improvement in DUs with fat grafting [113, 114] . In a small case series of nine patients (with 15 DUs), autologous fat grafting (to promote tissue repair) was performed between 2 and 8 months post-DU development [113] . Grafting was associated with complete healing of 10 DUs and 550% improvement in two DUs within 812 weeks (although of note, patients also received i.v. iloprost) [113] . In a single-centre, openlabel pilot study of 40 patients (11 with SSc and ischaemic DUs), bone marrow mononuclear cells were administered into their ischaemic limbs [115] . Transplantation was well tolerated, with good improvement in pain visual analog scale score; although at 2 years of follow-up, recurrence of ischaemic disease was not uncommon (two patients), and one patient had required digital amputation.
Immunosuppression
Khor et al. [116] describe a case report in which treatment with rituximab (for severe internal organ disease) was associated with complete healing of refractory DUs. In a small case series of three patients, 6 months of treatment with tocilizumab was associated with clearance of all DUs in the two patients with active DUs (three and eight) at baseline [117] . Of 10 patients with SSc who received treatment with CSA, one patient was noted to have complete healing of their DUs [118] . There is insufficient evidence at present to recommend immunosuppressive therapy for DUs, and infected DUs are a relative contraindication.
Conclusion
In conclusion, DUs are a common and disabling manifestation of the underlying vascular disease in SSc. An increasing understanding of DU pathogenesis, together with identification of reliable biomarkers, will help to identify those patients at highest risk, with a view to early intervention strategies. Further work is required to improve the reliability of classification of DUs by rheumatologists (to facilitate clinical trials) and to explore the role for non-invasive imaging techniques. Patient education is crucial, and patients should be managed within a dedicated multidisciplinary team. Although there are a number of effective treatments for DUs, side effects are not uncommon, and patients may develop new DUs despite treatment. Future research is warranted to optimize the management of DUs, including (but not limited to) combination therapies and the development of locally acting treatments.
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